Third-Generation EGFR TKIs

Slides:

Advertisements

Similar presentations

Using Non-targeted Therapies in Targeted Lung Cancer Populations Nathan Pennell, M.D., Ph.D. September 6, 2014.

Advertisements

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.

Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.

Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)

Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.

Brian Boulmay, MD LSUHSC- New Orleans Section of Hematology & Oncology

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

A cura di Filippo de Marinis

N Engl J Med; Volume 373(17): ; October 22, 2015

Rosell R et al. Proc ASCO 2011;Abstract 7503.

Bladder Cancer: A New Era in Treatment

Patient Case 1 Patient Case 1: PET/CT Scan.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Advanced NSCLC Without Actionable Mutations

Fundamental Concepts in the Diagnosis of Advanced NSCLC

Assessing the Impact: New Data in T790+ NSCLC

Discussion Outline Cells of the Immune System.

Progression After Cancer Immunotherapy in Advanced NSCLC

Overall Program Goals. Overall Program Goals Current Approaches.

Metastatic Renal Cell Carcinoma

New Standards of Care in ALK-Translocated Advanced NSCLC

Updates in Lung Cancer: Insights From Vienna

Updates and Perspectives on Third-Generation EFGR TKIs in Advanced NSCLC.

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

The Evolving Role of Immunotherapy in NSCLC

Optimizing Management of Advanced Bladder Cancer

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

Moving Care Forward in Advanced NSCLC

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

Advancing the Treatment of IBD With Biologics

When Is Biologic Therapy Appropriate for HS?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Oncologia Polmonare – AOU S. Luigi Gonzaga, Orbassano (To)

Immune Checkpoint Inhibitors in Lung Cancer

Factor Xa Inhibitors in PAD

Putting Evidence Into Practice: Highlights From Toronto

Emerging Paradigms in ALK-Positive NSCLC

Progress of the NSCLC Revolution

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Patient Questions and Expert Answers in Psoriasis:

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Practical Guidance on the Management of Pan-Negative NSCLC

Proteasome Inhibitors and Patients

Preparing for Checkpoint Inhibitors in Breast Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External.

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Educational Objectives

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

ROS1 Translocations and NSCLC

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Lipids, the Heart, and the Kidney

Immune Checkpoint Inhibitors in Lung Cancer

Combining Immunotherapy and Chemotherapy in NSCLC

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Updates in Best Practices in Non-Small Cell Lung Cancer

Uncovering the Right Sequence

Presentation transcript:

Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

Third-Generation EGFR TKIs

EGFR Inhibitors Following Progression on EGFR-Directed Therapy Preliminary Efficacy Comparison

Antiangiogenic Agents in Advanced NSCLC

First-line Therapy in Advanced NSCLC

Targeting MET in Advanced NSCLC

Global Phase 3 Trial (METLung) Global Phase 3 Trial (METLung)* of Onartuzumab Plus Erlotinib in NSCLC Trial Design

METLung Trial Overall Survival Results

Crizotinib in Advanced MET-amplified NSCLC Patient Eligibility: NSCLC MET Amplification Cohort

Characteristics of Patients With ALK-Positive Disease; Second- Generation ALK Inhibitors

ASCEND-1 Trial: Ceritinib in ALK-Positive Advanced NSCLC Best Percentage Change From Baseline

Immune Checkpoint Inhibitor Therapy in Advanced NSCLC

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)